Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Miami |
---|---|
Information provided by: | University of Miami |
ClinicalTrials.gov Identifier: | NCT00520910 |
With this study we will like to determine if taking a dose of the study medication, called Polypodium leucotomos (PL), prevents some of the changes in the skin caused by the adverse effects of UVA, a type of ultraviolet light. Ultraviolet light is a form of radiation which is not visible to the human eye. The sun produces different types of ultraviolet radiation, and UVA is one of them. More than 95% of the solar UV energy that reaches our skin is from the UVA type. UVA penetrates cloud cover and glass windows.
PL extract comes from a tropical fern plant grown in Central and South America, and it is a dietary supplement available in the US. No side effects have been reported with Polypodium leucotomos extract since becoming commercially available in 1982. Also, PL extract was approved for oral use by the Institutional Review Board of The Massachusetts General Hospital, Boston, for studies by Harvard Medical School faculty in human volunteers that were carried out for a period of two years, using artificial light and sunlight as ultraviolet sources.
This is an investigator-blinded study, which means that the doctor evaluating you will not know if you are receiving the study medication or not. Another doctor will be supplying you with the medication and discussing any problems that you may have with the medication.
You will be assigned to one of the two treatment groups. The group will be assigned by chance and you will have a one in two chances of receiving either the study medication or no treatment.
Condition | Intervention | Phase |
---|---|---|
Aging Skin Abnormalities |
Drug: Polypodium leucotomos Other: No Treatment |
Phase II |
Study Type: | Interventional |
Study Design: | Basic Science, Randomized, Single Blind (Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Single-Blind Study Determining the Efficacy of Polypodium Leucotomos Extract Supplement in Decreasing UVA Premutagenic and Photoaging Markers |
Estimated Enrollment: | 10 |
Study Start Date: | August 2007 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Subject is given a 7.5 mg/kg dose of Polypodium leucotomos.
|
Drug: Polypodium leucotomos
Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
|
2: No Intervention
Subject is not given any treatment.
|
Other: No Treatment
Patient is not given any treatment.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
University of Miami Skin Research Group Office | |
Miami, Florida, United States, 33136 |
Principal Investigator: | Brian Berman, M.D., Ph.D. | University of Miami, Department of Dermatology and Cutaneous Surgery |
Responsible Party: | University of Miami Miller School of Medicine ( Brian Berman, M.D., Ph.D. ) |
Study ID Numbers: | 20070203 |
Study First Received: | August 24, 2007 |
Last Updated: | June 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00520910 |
Health Authority: | United States: Institutional Review Board |
Polypodium leucotomos, Ultraviolet Rays, Heliocare, calaguala, anapsos Skin Aging and Damage |
Skin Diseases Skin Abnormalities Congenital Abnormalities |